Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...

A popular diabetes drug just got a major new approval—and it could be a game-changer for millions of Americans at risk for ...

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...